Tyrosine kinase inhibitors significantly increase the responsiveness of lung adenocarcinomas with mutant epidermal growth factor receptors, but they do not seem to improve survival for unselected individuals [58]. The gene discussed is EGFR; the disease is lung adenocarcinoma.